EPS for AMAG Pharmaceuticals, Inc. (AMAG) Expected At $-0.10

October 14, 2017 - By Louis Casey

 EPS for AMAG Pharmaceuticals, Inc. (AMAG) Expected At $ 0.10
Investors sentiment decreased to 1.09 in Q2 2017. Its down 0.18, from 1.27 in 2017Q1. It dropped, as 26 investors sold AMAG Pharmaceuticals, Inc. shares while 50 reduced holdings. 20 funds opened positions while 63 raised stakes. 41.85 million shares or 5.01% more from 39.85 million shares in 2017Q1 were reported.
Bridgeway Cap Management invested in 0.02% or 75,500 shares. Manufacturers Life Co The stated it has 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Acadian Asset Ltd Company holds 0.1% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 1.22M shares. Clark Estates Ny reported 150,100 shares. Wellington Group Ltd Liability Partnership invested in 52,037 shares. Loomis Sayles And Ltd Partnership holds 152 shares. Susquehanna Interest Gru Ltd Liability Partnership has invested 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Natl Bank Of America Corporation De stated it has 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Financial Bank Of Montreal Can owns 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 116,052 shares. Us Fincl Bank De accumulated 2,488 shares or 0% of the stock. Canada Pension Plan Inv Board stated it has 20,800 shares. Moreover, California Employees Retirement Sys has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 82,800 shares. Morgan Stanley has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Moreover, Teachers Retirement Of The State Of Kentucky has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Riverhead Cap Management Limited Liability, Delaware-based fund reported 2,496 shares.

Since May 1, 2017, it had 0 buys, and 1 insider sale for $46,235 activity. On Monday, May 1 the insider Krop Julie sold $46,235.

Investors wait AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report on November, 2. its quarterly earnings Wall Street analysts expect $-0.10 EPS, down $0.53 or 123.26 % from last year’s $0.43 same quarter earnings. AMAG Pharmaceuticals, Inc.’s Wall Street analysts see -75.00 % EPS growth, taking into account the $-0.40 EPS reproted in the previous quarter, The stock decreased 4.57% or $0.8 during the last trading session, reaching $16.7. About 956,304 shares traded or 6.54% up from the average. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 3.00% since October 14, 2016 and is uptrending. It has underperformed by 13.70% the S&P500.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage

Among 10 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. AMAG Pharmaceuticals had 28 analyst reports since August 18, 2015 according to SRatingsIntel. On Monday, June 26 the stock rating was maintained by Cantor Fitzgerald with “Hold”. Morgan Stanley initiated AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Friday, September 8 with “Buy” rating. The rating was maintained by Jefferies on Thursday, August 11 with “Buy”. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Buy” rating given on Thursday, October 27 by Needham. The rating was maintained by Cantor Fitzgerald with “Hold” on Monday, July 24. Jefferies maintained it with “Buy” rating and $3400 target in Tuesday, June 6 report. The rating was maintained by Leerink Swann on Wednesday, May 4 with “Outperform”. As per Tuesday, August 18, the company rating was initiated by Jefferies. The company was downgraded on Monday, January 9 by Raymond James. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Strong-Buy” rating by Zacks on Wednesday, August 19.

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The company has market cap of $589.32 million. The Company’s segment is the manufacture, development and commercialization of services and products for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. It currently has negative earnings. The Company’s offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena ; services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Another recent and important AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) news was published by Thestreet.com which published an article titled: “Commit To Purchase AMAG Pharmaceuticals At $12, Earn 13.2% Annualized Using …” on October 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com